

Changing Treatment Paradigms for Patients with Multiple Myeloma

February 10, 2023 | 4:00 PM EST

Currently, there is no cure for multiple myeloma, but there are treatment options that can help people with the disease live longer, healthier lives. Stem cell transplant is a standard of care for eligible patients. However, over half of those who are newly diagnosed with multiple myeloma are not eligible for transplant due to age or other major health problems, such as heart, lung, liver, or kidney disease.

In this interactive session, faculty will introduce a case study after which learners should be able to:

1. Discuss first- and second-line therapy for patients who are ineligible for transplants.
2. Discern the difference between administering subcutaneous daratumumab vs the IV form.
3. Describe how to administer subcutaneous daratumumab.

Agenda

4:00 **Welcome and Introductions**

4:10 **Case Presentation and Management Discussion**

Eden Biltibo, MD

PGY-6 Hematology/Oncology Clinical Fellow

Vanderbilt University Medical Center

Andrew Yee, MD

Clinical Director, Center for Multiple Myeloma

Assistant Professor of Medicine

Harvard Medical School

4:30 **Pharmacology Overview, Administration and Potential Adverse Effects**

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist

Winship Cancer Institute of Emory University

4:45 **Questions and Answers**

4:55 Closing Remarks

This activity is developed through a collaboration between The Association of Community Cancer Centers and The Leukemia & Lymphoma Society.